Microbot Medical (MBOT, Financial) has enhanced its U.S. commercial leadership team with the appointment of two senior executives. This strategic move aligns with the company’s preparations for a U.S. commercial launch, which is anticipated following the U.S. Food and Drug Administration's decision expected in the second quarter of 2025.
Allison Rosefort has been appointed as Vice President of Marketing, marking a new addition to the company's structure. Mrs. Rosefort will handle downstream marketing and brand management strategies, reporting directly to Harel Gadot, the company's CEO, President, and Chairman. Her previous experience includes a significant role as Senior Director of Product Marketing & Commercialization at Topcon Healthcare.
In another strategic hire, Lisa Dobbins joins as Director of Human Resources. Her responsibilities will include assisting in the development of the company's commercial infrastructure and U.S. team expansion. Ms. Dobbins will report to Naama Moav, Vice President of Human Resources, bringing with her experience as the HR Business Partner for Global Operations and Quality at Integra LifeSciences.
These appointments come shortly after Paul Mullen was named Vice President of Sales, reinforcing Microbot Medical’s commitment to establishing a robust commercial team in anticipation of its forthcoming U.S. market activities.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 1 analysts, the average target price for Microbot Medical Inc (MBOT, Financial) is $9.00 with a high estimate of $9.00 and a low estimate of $9.00. The average target implies an upside of 339.02% from the current price of $2.05. More detailed estimate data can be found on the Microbot Medical Inc (MBOT) Forecast page.
Based on the consensus recommendation from 1 brokerage firms, Microbot Medical Inc's (MBOT, Financial) average brokerage recommendation is currently 2.0, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
